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The comments of Kolominsky-Rabas and Caro [1] on
the third edition of the Hanover Consensus provide an
impression of the current nervousness and subtle posi-
tioning games of different stakeholders in Germany
while discussing the use of economic evaluation tech-
niques in medical care. As both authors present to the
readers of their comment a strong belief that the Insti-
tute’s recently issued guidelines reﬂect the will of the
sovereign and leave no room for discussion nor inter-
pretation of their own methods, we intend to give a
brief insight into some ﬂaws of their own methods, as
they are ignoring decades of health economic as well as
economic research.
The Hanover Consensus in its tradition is a consen-
sus of a large group of researchers and representatives
from sickness funds, physicians’ associations as well as
the industry. It does not duplicate textbook knowl-
edge, nor does it interfere with the interest of the
Institute for Quality and Efﬁciency in Health Care
(IQWiG) in deriving disease-speciﬁc cost–beneﬁt thres-
holds with methods, which will be unique worldwide,
because they have never been used before in, or any-
where outside of, Germany. The Hanover Consensus is
widely accepted in Germany; it became part of publi-
cation guidelines of scientiﬁc health economic journals
and was referred to when the tool of cost–beneﬁt
analyses was implemented by the law. The various
editions of the Hanover Consensus were even quoted
in the current IQWiG methods paper itself.
As just mentioned, about 10 months after the new
law became effective and the Hanover Consensus was
released in Germany, the IQWiG has published a ﬁrst
draft of a shell of a methods paper, which is currently
passionately debated in Germany.
One of the reasons why it is so hotly debated is
because the technical annex that is supposed to contain
all the important information, is only to be published
after the end of the appeal period. In addition to
breaking transparency rules, the recently published
ﬁrst draft of the IQWiG methods paper contains very
little information on methodological issues, a point
that the authors level at the Consensus. Furthermore,
the IQWiG paper concentrates on trying to explain
why a general threshold (e.g., “x” Euro per qualify-
adjusted life-year) would not be feasible in the context
of the German health-care system. The alternative pre-
sented leads to a set of indication-speciﬁc thresholds,
derived with the help of a vaguely founded efﬁciency
frontier which lines up earlier available drugs merely
on historical efﬁcacy data. As a result of that failure to
address economic theory, the concept has been rejected
by a wide phalanx of health economists around the
world––including members of the German Association
of Health Economics. According to the German Social
Law, the IQWiG is responsible for only the assessment,
not for the appraisal. The latter is done by the Federal
Joint Committee (G-BA) and the Federal Association
of Sickness Funds, which is allowed to set maximum
reimbursement prices for drugs.
Those institutions will have to make value judg-
ments, regardless of the evaluation method used in the
assessment, when they want to fulﬁl their legal respon-
sibilities. With that in mind, it is common practice
around the world that the perspective of analysis is
chosen by the decision-making body and not by scien-
tists issuing guidance on health economic methods.
The economist is only the messenger within the bound-
aries of broadly socially accepted methods. This mis-
understanding of the Consensus reﬂects a lack of
experience the IQWiG has in conducting such studies,
which we happily will discuss with them.
To be absolutely clear on one issue: we appreciate
the fact that the IQWiG has come forward with a
concept of its own to fuel discussion on this very
crucial subject in implementing cost-effectiveness
analyses, within the assessment of costs and beneﬁts in
Germany. This discussion has to be engaged in openly,
as the results of this process have repercussions on the
provision of health care to all of our citizens.
With that in mind, we strongly disagree with the
authors’ statement that the Hanover Consensus is
doomed from the start to end up “. . . as a search for
the lowest common denominator.” We have to call to
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mind that more than 70 researchers agreed to a scien-
tiﬁc guideline aiming at setting areas where principles
are unambiguous from experts to other experts in the
ﬁeld of health economics without repeating textbook
knowledge which Kolominsky-Rabas and Caro ask us
to quote.
The IQWiG positions itself in having legal
autonomy in setting up methods and speaking for
reimbursement decision-makers in Germany and
therefore denying any relevance of other methodologi-
cal approaches apart from their own. Decision-makers
in that respect in Germany, from a legal standpoint,
can be only sickness funds (and their legal bodies) and
above all the G-BA, which is the self-governing body
giving assignments to the IQWiG.
Among the members and therefore coauthors of the
Hanover Consensus Group are several high-ranking
current and also recent members of the G-BA as well as
the Chief Executive Ofﬁcers of all large sickness funds
in Germany, representing almost 80% of those covered
by the Statutory Health Insurance. Even one of the
members of the International Advisory Board, which
Caro is coordinating, is a member and therefore coau-
thor of the Hanover Consensus.
These people represent the legal entities to which
the IQWiG has to present its methods, and they were
sufﬁciently conﬁdent in the soundness of the consensus
to endorse it, thereby fostering the application of
methods relevant to them as decision-makers within
the German health-care system.
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